Theralase Technologies (Tsxv: Tlt)

Theralase Technologies (Tsxv: Tlt) company information, Employees & Contact Information

Theralase® Technologies is a Canadian clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers. We strive to continuously improve the quality of life for those afflicted with cancer by focusing our research and development on preventing, alleviating and treating diseases. Serving our higher purpose to bring hope for cancer treatments to light. Founded in 1994, Theralase’s operations are divided into two divisions: the production of therapeutic laser technology for commercial applications, and the research and development of laser-based technologies for the destruction of cancer cells and other disease states. Theralase® is focused on the discovering, developing and aiming for commercialization of Anti-Cancer therapies using light-activated PhotoDynamic Compounds and their associated drug formulations to safely and effectively treat patients afflicted with cancer.

Company Details

Employees
34
Founded
-
Address
41 Hollinger Road, Toronto,on M4b 3g4,canada
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Toronto, ON
Looking for a particular Theralase Technologies (Tsxv: Tlt) employee's phone or email?

Theralase Technologies (Tsxv: Tlt) Questions

News

Theralase Completes Annual General and Special Meeting - Yahoo Finance

Theralase Completes Annual General and Special Meeting Yahoo Finance

Theralase(R) Releases 2Q2025 Financial Statements - Newsfile

Theralase(R) Releases 2Q2025 Financial Statements Newsfile

Theralase(R) 1Q2025 Financial Statements - Newsfile

Theralase(R) 1Q2025 Financial Statements Newsfile

Theralase(R) Releases 2024 Annual Financial Statements - Yahoo Finance

Theralase(R) Releases 2024 Annual Financial Statements Yahoo Finance

Page not found - Factor Thisâ„¢ - FinancialContent

Page not found - Factor Thisâ„¢ FinancialContent

Theralase to Present at Alpha North Investor Conference - ACCESS Newswire

Theralase to Present at Alpha North Investor Conference ACCESS Newswire

Groundbreaking Herpes Treatment Success: Theralase's Ruvidar Shows 100% Healing Rate - Stock Titan

Groundbreaking Herpes Treatment Success: Theralase's Ruvidar Shows 100% Healing Rate Stock Titan

Theralase(R) Closes Non-Brokered Private Placement - Newsfile

Theralase(R) Closes Non-Brokered Private Placement Newsfile

Theralase(R) Demonstrates Effective Treatment of Herpes - Yahoo Finance

Theralase(R) Demonstrates Effective Treatment of Herpes Yahoo Finance

Theralase's Anti-Herpes Drug Shows 'Better Than Acyclovir' Results - Major Research Milestone - Stock Titan

Theralase's Anti-Herpes Drug Shows 'Better Than Acyclovir' Results - Major Research Milestone Stock Titan

Theralase Provides Update on ITA Application to Health Canada - ACCESS Newswire

Theralase Provides Update on ITA Application to Health Canada ACCESS Newswire

Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug - Stock Titan

Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug Stock Titan

Theralase expands board of directors with strong financing capabilities - Chiropractic Economics

Theralase expands board of directors with strong financing capabilities Chiropractic Economics

Theralase(R) Announces Appointment of New Independent Director - Yahoo Finance

Theralase(R) Announces Appointment of New Independent Director Yahoo Finance

Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments - Newsfile

Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments Newsfile

Revolutionary Herpes Drug Shows Superior Results: Challenges $2.8B Market Leaders - Stock Titan

Revolutionary Herpes Drug Shows Superior Results: Challenges $2.8B Market Leaders Stock Titan

Theralase Partners with University of Toledo in Cancer Research - ACCESS Newswire

Theralase Partners with University of Toledo in Cancer Research ACCESS Newswire

Top Theralase Technologies (Tsxv: Tlt) Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant